Download pdf
Modern Innovations in Vaccine Development: Exploring New Trends and Technologies
- 1 School of Biological Sciences, University of Aberdeen, Aberdeen, UK
* Author to whom correspondence should be addressed.
Abstract
Since the 18th century, vaccines have played a crucial role in preventing infectious diseases, with the earliest example being Edward Jenner’s pioneering use of the cowpox vaccine to prevent smallpox in 1796. Vaccines work by inducing specific immune responses, effectively preventing the spread of various infectious diseases and protecting the health of individuals and communities. However, traditional vaccine technologies face certain limitations, such as reversion to virulence and long production cycles. In recent years, rapid advances in biotechnology have introduced new vaccine technologies, including mRNA, DNA, nanoparticle, and mosaic vaccines. These innovative technologies are expected to enhance the safety and efficacy of vaccines and accelerate development times. This review explores the latest trends and technological advancements in vaccine development, highlighting the potential applications of these new technologies. By addressing the challenges faced by traditional vaccines and emphasizing the benefits of emerging approaches, this paper aims to provide valuable insights for vaccine research and public health policy, ultimately enhancing global efforts in disease prevention and control.
Keywords
Vaccines, mRNA, DNA, nanoparticles, delivery systems.
[1]. Schleiff, M, Olateju, A, Decker, E, Neel, A H, Oke, R, Peters, M A, ... and Alonge, O 2020 A multi-pronged scoping review approach to understanding the evolving implementation of the Smallpox and Polio eradication programs: what can other Global Health initiatives learn?. BMC public health, 20, 1-13.
[2]. Suares, J E, Khan, S, Aadrika, A, Poojari, P G, Rashid, M, and Thunga, G 2024 Vaccine-associated paralytic poliomyelitis in oral polio vaccine recipients: disproportionality analysis using VAERS and systematic review. Expert Opinion on Drug Safety, 1-13.
[3]. Delany, I, Rappuoli, R, and De Gregorio, E 2014 Vaccines for the 21st century. EMBO molecular medicine, 6(6), 708-720.
[4]. Mohsen, M O, Zha, L, Cabral-Miranda, G, and Bachmann, M F 2017 Major findings and recent advances in virus–like particle (VLP)-based vaccines. In Seminars in immunology (Vol. 34, pp. 123-132). Academic Press.
[5]. Rauch, S, Jasny, E, Schmidt, K E, and Petsch, B 2018 New vaccine technologies to combat outbreak situations. Frontiers in immunology, 9, 1963.
[6]. Xu, S, Yang, K, Li, R, and Zhang, L 2020 mRNA vaccine era—mechanisms, drug platform and clinical prospection. International journal of molecular sciences, 21(18), 6582.
[7]. Chennakesavulu, P V, Cuddapah, G V, Keesara, M R, Inampudi, J V, Arremsetty, A, Moka, S, and Miryala, S 2022 COVID-19 Vaccine Clinical Trials: A Bird’s Eye Perspective. Cureus, 14(8).
[8]. Qiu, X, Xu, S, Lu, Y, Luo, Z, Yan, Y, Wang, C, and Ji, J 2022 Development of mRNA vaccines against respiratory syncytial virus (RSV). Cytokine & Growth Factor Reviews, 68, 37-53.
[9]. Eusébio, D, Neves, A R, Costa, D, Biswas, S, Alves, G, Cui, Z, and Sousa, Â 2021 Methods to improve the immunogenicity of plasmid DNA vaccines. Drug Discovery Today, 26(11), 2575-2592.
[10]. Tebas, P, Yang, S, Boyer, J D, Reuschel, E L, Patel, A, Christensen-Quick, A, ... and Humeau, L M 2021 Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, Phase 1 clinical trial. EClinicalMedicine, 31.
[11]. Gary, E N, and Weiner, D B 2020 DNA vaccines: prime time is now. Current Opinion in Immunology, 65, 21-27.
[12]. Liu, X, Zhao, T, Wang, L, Yang, Z, Luo, C, Li, M, ... and Shu, Y 2023 A mosaic influenza virus-like particles vaccine provides broad humoral and cellular immune responses against influenza A viruses. npj Vaccines, 8(1), 132.
[13]. Julg, B, Stephenson, K E, Tomaka, F, Walsh, S R, Sabrina Tan, C, Lavreys, L, ... and Barouch, D H 2024 Immunogenicity of 2 therapeutic mosaic HIV-1 vaccine strategies in individuals with HIV-1 on antiretroviral therapy. npj Vaccines, 9(1), 89.
[14]. Stephenson, K E, Wegmann, F, Tomaka, F, Walsh, S R, Tan, C S, Lavreys, L, ... and Barouch, D H 2020 Comparison of shortened mosaic HIV-1 vaccine schedules: a randomised, double-blind, placebo-controlled phase 1 trial (IPCAVD010/HPX1002) and a preclinical study in rhesus monkeys (NHP 17–22). The Lancet HIV, 7(6), e410-e421.
[15]. Kessler, A L, Bruno, M J, and Buschow, S I 2020 The potential of soluble human leukocyte antigen molecules for early cancer detection and therapeutic vaccine design. Vaccines, 8(4), 775.
[16]. Zhu, Y J, Li, X, Chen, T T, Wang, J X, Zhou, Y X, Mu, X L, ... and Liu, J Y 2023 Personalised neoantigen‐based therapy in colorectal cancer. Clinical and Translational Medicine, 13(11), e1461.
[17]. Blass, E, and Ott, P A 2021 Advances in the development of personalized neoantigen-based therapeutic cancer vaccines. Nature reviews Clinical oncology, 18(4), 215-229.
[18]. Tenchov, R, Bird, R, Curtze, A E, and Zhou, Q 2021 Lipid nanoparticles─ from liposomes to mRNA vaccine delivery, a landscape of research diversity and advancement. ACS nano, 15(11), 16982-17015.
[19]. He, Y, Zhang, W, Xiao, Q, Fan, L, Huang, D, Chen, W, and He, W 2022 Liposomes and liposome-like nanoparticles: From anti-fungal infection to the COVID-19 pandemic treatment. Asian Journal of Pharmaceutical Sciences, 17(6), 817-837.
[20]. Tornesello, A L, Tagliamonte, M, Tornesello, M L, Buonaguro, F M, and Buonaguro, L 2020 Nanoparticles to improve the efficacy of peptide-based cancer vaccines. Cancers, 12(4), 1049.
[21]. Wu, Z, and Li, T 2021 Nanoparticle-mediated cytoplasmic delivery of messenger RNA vaccines: challenges and future perspectives. Pharmaceutical Research, 38(3), 473-478.
[22]. Ye, Y, Ma, Y, and Zhu, J 2022 The future of dry powder inhaled therapy: Promising or discouraging for systemic disorders?. International journal of pharmaceutics, 614, 121457.
[23]. Nainwal, N, Sharma, Y, and Jakhmola, V 2022 Dry powder inhalers of antitubercular drugs. Tuberculosis, 135, 102228.
[24]. Nainwal, N 2022 Treatment of respiratory viral infections through inhalation therapeutics: Challenges and opportunities. Pulmonary Pharmacology & Therapeutics, 77, 102170.
[25]. Mansoor, I, Eassa, H A, Mohammed, K H, Abd El-Fattah, M A, Abdo, M H, Rashad, E, ... and Ghoneim, O 2022 Microneedle-based vaccine delivery: Review of an emerging technology. Aaps Pharmscitech, 23(4), 103.
[26]. Menon, I, Bagwe, P, Gomes, K B, Bajaj, L, Gala, R, Uddin, M N, ... and Zughaier, S M 2021 Microneedles: a new generation vaccine delivery system. Micromachines, 12(4), 435.
Cite this article
Dou,X. (2024). Modern Innovations in Vaccine Development: Exploring New Trends and Technologies. Theoretical and Natural Science,61,1-9.
Data availability
The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.
Disclaimer/Publisher's Note
The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of EWA Publishing and/or the editor(s). EWA Publishing and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
About volume
Volume title: Proceedings of the 4th International Conference on Biological Engineering and Medical Science
© 2024 by the author(s). Licensee EWA Publishing, Oxford, UK. This article is an open access article distributed under the terms and
conditions of the Creative Commons Attribution (CC BY) license. Authors who
publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons
Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this
series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published
version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial
publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and
during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See
Open access policy for details).